Gastrointestinal stromal tumor

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. They account for ~5% of all sarcomas, and are mostly found within stomach and mid-distal small bowel. They respond remarkably well to chemotherapy.

Previously these tumors have been variably referred to as leiomyomas, leiomyosarcomas, and leiomyoblastomas, as they were difficult to differentiate on histopathology until a characteristic expression of c-KIT and CD34 antigens was identified.

  • incidence
    • overall uncommon when compared to gastrointestinal carcinoma, estimated ~ 0.0015% 13
    • small autopsy reports suggest the incidence of tiny subclinical tumors ("tumorlets") may be as high as 23% in those over 50 years old
  • age
    • usually occur after 40 years of age, most seen in older patients 1
    • may present earlier and often multiple in tumor syndromes (see below) 
  • gender
    • equal in both male and female incidence, with possible slight male predilection
  • by location
    • esophagus - uncommon (versus leiomyomas)
    • stomach - most common site, most common gastric sarcoma
    • small bowel - second most common site
    • colon and rectum - most common rectal sarcoma

Clinical presentation is variable and reflects the variability of appearance, location, and biological behavior.

  • small tumors are more likely to be asymptomatic, regardless of location
  • tend to grow intramural, bulging intraluminal or extramural if large enough
    • uncommon to cause dysphagia or bowel obstruction until very large
  • larger tumors known to ulcerate and cause gastrointestinal hemorrhage 1
  • may present with non-specific gastrointestinal symptoms (e.g. abdominal pain, nausea, vomiting)
  • aggressive tumors may present with metastases or symptoms relating to local disease  1

GISTs are typically submucosal tumors, and the overlying mucosa often remains intact on pathological and imaging assessment.

They are believed to arise from the interstitial cells of Cajal 2-3, with 95% staining positive for CD117 (c-KIT) and 70% for CD34 2. The former is a tyrosine kinase growth factor receptor and the target of ST-571 (imatinib/Gleevec/GlivecTM1.

Grading GISTs requires assessment of both tumor size and mitotic index 3. Smaller lesions have less aggressive biological behavior, as do stomach GISTs when compared to tumors elsewhere along the gastrointestinal tract 3.

They are rounded with frequent hemorrhage. Larger tumors may also demonstrate necrosis and cystic change 1-2. Size is variable, ranging from 1 to 30 cm 1.

Histology demonstrates a relatively cellular tumor composed of spindle cells (70-80%) and plump epithelioid cells (20-30%) 1-2. They appear to arise from the muscularis propria layer.

The vast majority of GISTs are sporadic; however, they are recognized to occur in the following syndromes 2:

GISTs occur anywhere along the gastrointestinal tract. Common sites of involvement include 8:

In addition, extra-gastrointestinal GISTs are known to occur in the mesenteryomentum, and retroperitoneum 1,4. Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs 7.

Specific appearances will vary according to location (see above), but in general, these tumors appear as rounded soft tissue masses, arising from the wall of a hollow viscus (most commonly the stomach) with an endoluminal or exophytic growth. Mucosal ulceration is present in 50% of cases 1 with large necrotic cavities communicating with the lumen also seen.

When large, secondary signs of tumor may visualized by radiograph, e.g. soft tissue density displacing bowel loops.

On upper abdominal studies, filling defect projecting from the wall of the stomach may be seen, with overlying ulceration or cavitation. The tumor margins are normally seen as smooth and may form right or obtuse angles with the adjacent mucosa due to its intramural origin.

Appearances vary with size and location. Typically the mass is of soft tissue density with central areas of lower density when necrosis is present (usually in larger tumors) that occasionally appear as fluid-fluid levels.

As the tumors are often exophytic, it can be difficult to delineate them on CT if the stomach is distended with barium, though the non-enhancing central necrotic area may be helpful. A deep crescent-shaped ulceration demonstrating an internal air-fluid level may be referred to as the Torricelli-Bernoulli sign 9.

Enhancement is typically peripheral (due to central necrosis) 1. Calcification is uncommon (3%) 1.

Metastases (distant, peritoneal, omental) or direct invasion into adjacent organs may be seen in more aggressive lesions. Lymph node enlargement is not a feature 1.

The presence of necrosis, hemorrhagic and cystic change make appearances variable:

  • T1
    • low signal intensity solid component
    • enhancement is usually present, and predominantly peripheral in larger lesions
  • T2: high signal intensity solid component

Choi response criteria used to assess the treatment 11.

Surgical en-bloc resection is the primary mode of therapy for GISTs 4. Up to 50% of all GISTs will have evidence of metastatic disease at the time of presentation 3, which significantly impacts prognosis.

Adjuvant chemotherapy with ST-571 (imatinib) is effective in the majority of cases and has had a dramatic impact on prognosis even with only one year of therapy, reducing recurrence at one year from 17% to 3% 4. Longer treatment regimes (2-3 years of imatinib) are currently under investigation 4. Other second-line agents (e.g. sunitinib) are also being studied and used for patients with imatinib-resistant tumors.

Historically, before ST-571 (imatinib) up to 85% of tumors would locally recur or develop subsequent distal metastases despite treatment 3,4 and had proven to be resistant to standard chemotherapy 4.

FDG-PET may be used in monitoring treatment response and is considered superior to CT in monitoring treatment response in the initial phases of treatment 10.

General imaging differential considerations include:

Share article

Article information

rID: 6758
Tag: stomach
Synonyms or Alternate Spellings:
  • GIST
  • Gastrointestinal stromal tumours
  • Gastrointestinal stromal tumor
  • Gastrointestinal stromal tumour (GIST)
  • Gastrointestinal stromal tumors
  • GIST's

Support Radiopaedia and see fewer ads

Cases and figures

  • Figure 1: gross pathology - gastric GIST
    Drag here to reorder.
  • Case 1
    Drag here to reorder.
  • Case 2
    Drag here to reorder.
  • Case 3: GIST
    Drag here to reorder.
  • Case 4: jejunal GIST
    Drag here to reorder.
  • Case 5: H & E stain
    Drag here to reorder.
  • Case 6: at endoscopy
    Drag here to reorder.
  • Case 7
    Drag here to reorder.
  • Case 8
    Drag here to reorder.
  • Case 9: on ultrasound
    Drag here to reorder.
  • Case 10
    Drag here to reorder.
  • Case 11
    Drag here to reorder.
  • Case 12: small omental lesion
    Drag here to reorder.
  • Case 13: large intra-abdominal GIST
    Drag here to reorder.
  • Case 14: esophageal GIST - arrowed
    Drag here to reorder.
  • Case 15: duodenal GIST
    Drag here to reorder.
  • Case 16: with hepatic metastases
    Drag here to reorder.
  • Case 17
    Drag here to reorder.
  • Case 18: on ultrasound
    Drag here to reorder.
  • Case 19
    Drag here to reorder.
  • Case 21
    Drag here to reorder.
  • Case 22
    Drag here to reorder.
  • Case 23: gastric
    Drag here to reorder.
  • Case 24
    Drag here to reorder.
  • Updating… Please wait.

     Unable to process the form. Check for errors and try again.

     Thank you for updating your details.